KY-226

SKU: orb1299577

Description

KY-226 is a potent and selective small molecule inhibitor of PTP1B, exhibiting an IC50 of 0.25 µM. It serves as a valuable research tool for studying type 2 diabetes and obesity in both cellular and animal models, based on its role in insulin and leptin signaling pathways.

Research Area

Metabolism Research

Key Properties

• CAS Number: 1621673-53-7
• MW: 481.67
• Purity: 99.40%
• Formula: C₂₇H₃₁NO₃S₂
• SMILES: CCCCCCS(=O)(=O)NC(=O)c1ccc(CSCc2ccc(cc2)-c2ccccc2)cc1
• Target: Phosphatase
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.15 mM);DMSO:25 mg/mL (51.9 mM)

Bioactivity

• Target IC50:
  PTP1B:0.25 μM
• In Vivo:
  In db/db mice, the oral administration of KY-226 (10 and 30 mg/kg/day, 4 weeks) significantly reduced plasma glucose and triglyceride levels as well as hemoglobin A1c values without increasing body weight gain, while pioglitazone exerted similar effects with increases in body weight gain. KY-226 attenuated plasma glucose elevations in the oral glucose tolerance test. KY-226 also increased pIR and phosphorylated Akt in the liver and femoral muscle. In high-fat diet-induced obese mice, the oral administration of KY-226 (30 and 60 mg/kg/day, 4 weeks) decreased body weight gain, food consumption, and fat volume gain with increases in phosphorylated STAT3 in the hypothalamus.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

LPS, neurons, KY226, KY-226, KY 226, inhibit, Inhibitor, insulin, leptin, anti-obesity, anti-diabetic, Akt, phosphorylated, Phosphatase, PTP1B, ZO-1

Compound Identifiers

PubChem CID

76955652